OncoCyte Corporation Releases Transcript for Q1 2025 Earnings Call

Reuters

2025/05/15

<a href="https://laohu8.com/S/OCX">OncoCyte Corporation</a> Releases Transcript for Q1 2025 Earnings Call

OncoCyte Corporation recently held its Q1 2025 Earnings Call, where executives and analysts gathered to discuss the company's financial performance and strategic direction. Key attendees included Joshua Riggs, President and CEO, Andrea James, CFO, and Ekkehard Schütz, Chief Science Officer, alongside analysts from BTIG LLC, Stephens Inc., Lake Street Capital Markets LLC, Needham & Co. LLC, and B. Riley Securities, Inc. During the call, CEO Joshua Riggs highlighted the company's continued progress on its 2025 plan, stating, "We've been heads down executing on our 2025 plan." Riggs expressed confidence in OncoCyte's direction, noting increased interest from potential corporate partners in their transplant and oncology technologies as "external validation" of their strategy. CFO Andrea James shared financial highlights, reporting that pharma services revenue of $2.1 million exceeded expectations. The call emphasized OncoCyte's commitment to building a valuable business through strategic investments and partnerships. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OncoCyte Corporation published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535788859"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535788859\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535788859?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 04:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535788859","market":"nz","top_or_hot":-1,"title":"OncoCyte Corporation Releases Transcript for Q1 2025 Earnings Call","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCX\">OncoCyte Corporation</a> Releases Transcript for Q1 2025 Earnings Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OncoCyte Corporation recently held its Q1 2025 Earnings Call, where executives and analysts gathered to discuss the company's financial performance and strategic direction. Key attendees included Joshua Riggs, President and CEO, Andrea James, CFO, and Ekkehard Schütz, Chief Science Officer, alongside analysts from BTIG LLC, Stephens Inc., Lake Street Capital Markets LLC, Needham &amp; Co. LLC, and B. Riley Securities, Inc. During the call, CEO Joshua Riggs highlighted the company's continued progress on its 2025 plan, stating, \"We've been heads down executing on our 2025 plan.\" Riggs expressed confidence in OncoCyte's direction, noting increased interest from potential corporate partners in their transplant and oncology technologies as \"external validation\" of their strategy. CFO Andrea James shared financial highlights, reporting that pharma services revenue of $2.1 million exceeded expectations. The call emphasized OncoCyte's commitment to building a valuable business through strategic investments and partnerships. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OncoCyte Corporation published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoCyte Corporation Releases Transcript for Q1 2025 Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoCyte Corporation Releases Transcript for Q1 2025 Earnings Call\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-15 04:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCX\">OncoCyte Corporation</a> Releases Transcript for Q1 2025 Earnings Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OncoCyte Corporation recently held its Q1 2025 Earnings Call, where executives and analysts gathered to discuss the company's financial performance and strategic direction. Key attendees included Joshua Riggs, President and CEO, Andrea James, CFO, and Ekkehard Schütz, Chief Science Officer, alongside analysts from BTIG LLC, Stephens Inc., Lake Street Capital Markets LLC, Needham &amp; Co. LLC, and B. Riley Securities, Inc. During the call, CEO Joshua Riggs highlighted the company's continued progress on its 2025 plan, stating, \"We've been heads down executing on our 2025 plan.\" Riggs expressed confidence in OncoCyte's direction, noting increased interest from potential corporate partners in their transplant and oncology technologies as \"external validation\" of their strategy. CFO Andrea James shared financial highlights, reporting that pharma services revenue of $2.1 million exceeded expectations. The call emphasized OncoCyte's commitment to building a valuable business through strategic investments and partnerships. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OncoCyte Corporation published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RILY","symbol_name":"BRC Group Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL5Ygjny:1","article_id":"2535788859","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535788859","pubTimestamp":1747255633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OncoCyte Corporation recently held its Q1 2025 Earnings Call, where executives and analysts gathered to discuss the company's financial performance and strategic direction. Key attendees included Joshua Riggs, President and CEO, Andrea James, CFO, and Ekkehard Schütz, Chief Science Officer, alongside analysts from BTIG LLC, Stephens Inc., Lake Street Capital Markets LLC, Needham & Co. LLC, and B. Riley Securities, Inc. During the call, CEO Joshua Riggs highlighted the company's continued progress on its 2025 plan, stating, \"We've been heads down executing on our 2025 plan.\" Riggs expressed confidence in OncoCyte's direction, noting increased interest from potential corporate partners in their transplant and oncology technologies as \"external validation\" of their strategy. CFO Andrea James shared financial highlights, reporting that pharma services revenue of $2.1 million exceeded expectations. The call emphasized OncoCyte's commitment to building a valuable business through strategic i","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RILY":"BRC Group Holdings, Inc."},"translate_title":"OncoCyte Corporation发布2025年第一季度收益看涨期权记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCX":0.9,"RILY":0.9},"content_text":"OncoCyte Corporation Releases Transcript for Q1 2025 Earnings Call\n    \n\n        OncoCyte Corporation recently held its Q1 2025 Earnings Call, where executives and analysts gathered to discuss the company's financial performance and strategic direction. Key attendees included Joshua Riggs, President and CEO, Andrea James, CFO, and Ekkehard Schütz, Chief Science Officer, alongside analysts from BTIG LLC, Stephens Inc., Lake Street Capital Markets LLC, Needham & Co. LLC, and B. Riley Securities, Inc. During the call, CEO Joshua Riggs highlighted the company's continued progress on its 2025 plan, stating, \"We've been heads down executing on our 2025 plan.\" Riggs expressed confidence in OncoCyte's direction, noting increased interest from potential corporate partners in their transplant and oncology technologies as \"external validation\" of their strategy. CFO Andrea James shared financial highlights, reporting that pharma services revenue of $2.1 million exceeded expectations. The call emphasized OncoCyte's commitment to building a valuable business through strategic investments and partnerships. The full transcript can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OncoCyte Corporation published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}